Article Details

AstraZeneca's Forxiga approved in the EU for chronic kidney disease

Retrieved on: 2021-08-09 06:11:15

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Forxiga approved in the EU for chronic kidney disease. View article details on hiswai:

Excerpt

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union ...

Article found on: www.directorstalkinterviews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up